Authors
Weijie Liu, Benjamin P Zuckerman, Art Schuermans, Gisela Orozco, Michael C Honigberg, John Bowes, Terence W O'Neill, Sizheng Steven Zhao
Published in
Osteoarthritis and cartilage open. Volume 8. Issue 4. Pages 100890. Epub Oct 24, 2026.
Abstract
Osteoarthritis (OA) is a leading cause of disability, yet no licensed therapies can prevent or slow its progression. We aimed to identify potential disease-modifying OA drug (DMOAD) targets by integrating genetic and differential protein abundance (DPA) evidence.
We evaluated genetically predicted perturbations of plasma protein levels using cis-protein quantitative trait loci (cis-pQTLs) across three European cohorts (UK Biobank Pharma Proteomics Project, deCODE, and Fenland) and outcome data from the Genetics of Osteoarthritis Consortium across 11 OA phenotypes. Following limit-of-detection and missingness filtering, DPA evaluated 2133 proteins in 7186 prevalent OA cases and 29,584 controls from UK Biobank. MR-prioritised proteins were further assessed using summary-data-based Mendelian randomisation (SMR) with OA joint-tissue eQTL data, alongside pathway, protein-interaction, and druggability analyses.
Cis-MR and colocalisation prioritised 81 proteins, of which 30 showed joint-tissue transcriptomic support in SMR analyses. DPA identified 1436 proteins associated with ≥1 OA phenotype, of which 1314 (91.5%) retained significance in sensitivity analyses. Seventeen proteins had matched MR and DPA support, including three Tier 1 druggable targets (DLK1, SOST, and TNFRSF9); seven of these had SMR support. EHBP1, LGALS3, and OGN showed concordant DPA and MR effects and cross-platform evidence. EHBP1, PCSK7 and ITIH4 emerged as under-recognised candidates. Pathway analyses recapitulated established OA processes, while drug enrichment identified hypothesis-generating compounds.
Integration of cis-MR, colocalisation, DPA, and tissue-specific transcriptomic evidence prioritised several potential OA therapeutic targets. DLK1, LGALS3, OGN and EHBP1 emerged as high-priority candidates, while EHBP1, PCSK7 and ITIH4 represent under-recognised candidates warranting functional investigation.
PMID:
43022691
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0